We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
- Recent SRPT Stock Price: $120.60
- Yearly Gain for SRPT stock: -22.69%
- Market Cap for SRPT stock: $11.32B
- P/E Ratio for SRPT stock: -20.79
Will SRPT's stock price go up? Is there an accurate SRPT stock forecast available?
TipRanks.com reports that Sarepta Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $169.75. The target pricing ranges from a high SRPT forecast of $177 down to a low forecast of $165. Sarepta Therapeutics, Inc. (SRPT)’s last closing stock price was $120.60 which would put the average price target at 40.75% upside.
In addition, TradingView issued a Neutral rating for SRPT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on SRPT stock.
Other analysts covering SRPT include:
- Kostas Biliouris of BMO Capital issued a Buy rating with the price target of $170 on 1 day ago
- Colin Bristow of UBS issued a Buy rating with the price target of $167 on 5 days ago
- Ritu Baral of TD Cowen issued a Buy rating with the price target of $165 on 6 days ago
If you are wondering if SRPT is a good stock to buy, here are 3rd party ratings for SRPT stock:
- TipRanks.com: Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding Sarepta Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for SRPT stock: Bearish
- Blogger Consensus for SRPT stock:
- Media Buzz for SRPT stock: Strong Buy
- Insider Signal for SRPT stock: Buying
- Investor Sentiment for SRPT stock: Positive
- Hedge Fund signal for SRPT stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on SRPT stock including scouring the social networks like SRPT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for SRPT stock chart >>
Summary: Teladoc Health, Inc. provides virtual access to high-quality care and expertise with a portfolio of services and solutions, covering medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company combines the latest in data and analytics with an award-winning user experience through a highly flexible technology platform. The company provides access to healthcare through its portfolio of five consumer brands 24 hours a day, seven days a week and 365 days a year. Its solutions are delivered with an approximate median response time of less than ten minutes in the United States for general medical inquiries from the time a member requests a general medical telehealth visit to the time they consult with a Teladoc Health network provider.
- Recent TDOC Stock Price: $14.54
- Yearly Gain for TDOC stock: -43.12%
- Market Cap for TDOC stock: $2.43B
- P/E Ratio for TDOC stock: -10.85
Will TDOC's stock price go up? Is there an accurate TDOC stock forecast available?
TipRanks.com reports that Teladoc Health, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $18.25. The target pricing ranges from a high TDOC forecast of $22 down to a low forecast of $17. Teladoc Health, Inc. (TDOC)’s last closing stock price was $14.54 which would put the average price target at 25.52% upside.
In addition, TradingView issued a Sell rating for TDOC stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on TDOC stock.
Other analysts covering TDOC include:
- Sarah James of Cantor Fitzgerald issued a Buy rating with the price target of $22 on 6 days ago
- Steve Baxter of Wells Fargo issued a Hold rating with the price target of $17 on 1 week ago
- Jim Kelly of Leerink Partners issued a Hold rating with the price target of $17 on 1 week ago
If you are wondering if TDOC is a good stock to buy, here are 3rd party ratings for TDOC stock:
- TipRanks.com: Hold
- TradingView.com: Sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 29% (73 out of 252)
What is the sentiment on the street regarding Teladoc Health, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for TDOC stock: Bullish
- Blogger Consensus for TDOC stock:
- Media Buzz for TDOC stock: Buy
- Insider Signal for TDOC stock: Balanced
- Investor Sentiment for TDOC stock: Negative
- Hedge Fund signal for TDOC stock: High Risk
The stock market is extremely volatile, and you need to do your own research on TDOC stock including scouring the social networks like TDOC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TDOC stock chart >>
Summary: Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic disease and hepatic infectious disease. The company's lead drug-Onpattro received regulatory approvals in the United States and Europe for the treatment of hereditary transthyretin-mediated amyloidosis in adults. The FDA approved Givlaari for acute hepatic porphyria. The FDA approved Oxlumo injection for subcutaneous use, for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients. Moreover, the company is evaluating inclisiran for hypercholesterolemia in partnership with The Medicines Company acquired by Novartis. The FDA approved Leqvio to reduce low-density lipoprotein cholesterol with two doses a year..
- Recent ALNY Stock Price: $148.49
- Yearly Gain for ALNY stock: -25.65%
- Market Cap for ALNY stock: $18.70B
- P/E Ratio for ALNY stock: -42.18
Will ALNY's stock price go up? Is there an accurate ALNY stock forecast available?
TipRanks.com reports that Alnylam Pharmaceuticals, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $231.40. The target pricing ranges from a high ALNY forecast of $395 down to a low forecast of $150. Alnylam Pharmaceuticals, Inc. (ALNY)’s last closing stock price was $148.49 which would put the average price target at 55.84% upside.
In addition, TradingView issued a Sell rating for ALNY stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALNY stock.
Other analysts covering ALNY include:
- Tiago Fauth of Wells Fargo issued a Hold rating with the price target of $161 on 1 day ago
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $395 on 1 day ago
- Kostas Biliouris of BMO Capital issued a Buy rating with the price target of $234 on 1 day ago
- Olivia Brayer of Cantor Fitzgerald issued a Hold rating with the price target of $150 on 1 week ago
If you are wondering if ALNY is a good stock to buy, here are 3rd party ratings for ALNY stock:
- TipRanks.com: Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding Alnylam Pharmaceuticals, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALNY stock: Bearish
- Blogger Consensus for ALNY stock:
- Media Buzz for ALNY stock: Neutral
- Insider Signal for ALNY stock: Selling
- Investor Sentiment for ALNY stock: Negative
- Hedge Fund signal for ALNY stock: High Risk
The stock market is extremely volatile, and you need to do your own research on ALNY stock including scouring the social networks like ALNY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALNY stock chart >>
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
- Recent BMRN Stock Price: $86.53
- Yearly Gain for BMRN stock: -8.24%
- Market Cap for BMRN stock: $16.33B
- P/E Ratio for BMRN stock: 99.46
Will BMRN's stock price go up? Is there an accurate BMRN stock forecast available?
TipRanks.com reports that BioMarin Pharmaceutical Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $116.50. The target pricing ranges from a high BMRN forecast of $128 down to a low forecast of $104. BioMarin Pharmaceutical Inc. (BMRN)’s last closing stock price was $86.53 which would put the average price target at 34.64% upside.
In addition, TradingView issued a Sell rating for BMRN stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN stock.
Other analysts covering BMRN include:
- Akash Tewari of Jefferies issued a Buy rating with the price target of $128 on 5 days ago
- Paul Matteis of Stifel Nicolaus issued a Buy rating with the price target of $109 on 1 week ago
- Jack Allen of Robert W. Baird issued a Buy rating with the price target of $104 on 1 week ago
If you are wondering if BMRN is a good stock to buy, here are 3rd party ratings for BMRN stock:
- TipRanks.com: Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 29% (74 out of 252)
What is the sentiment on the street regarding BioMarin Pharmaceutical Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for BMRN stock: Bullish
- Blogger Consensus for BMRN stock:
- Media Buzz for BMRN stock: Buy
- Insider Signal for BMRN stock: Buying
- Investor Sentiment for BMRN stock: Positive
- Hedge Fund signal for BMRN stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on BMRN stock including scouring the social networks like BMRN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BMRN stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================